REFERENCES
1. Gorman GS, Schaefer AM, Ng Y, et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol. 2015;77:753-9.
2. Mcfarland R, Taylor RW, Turnbull DM. A neurological perspective on mitochondrial disease. Lancet Neurol. 2010;9:829-40.
3. Heath O, Feichtinger RG, Achleitner MT, et al. Mitochondrial disorder diagnosis and management- what the pediatric neurologist wants to know. Eur J Paediatr Neurol. 2025;54:75-88.
4. Wen H, Deng H, Li B, et al. Mitochondrial diseases: from molecular mechanisms to therapeutic advances. Sig Transduct Target Ther. 2025;10:9.
5. Dimauro S, Schon EA, Carelli V, Hirano M. The clinical maze of mitochondrial neurology. Nat Rev Neurol. 2013;9:429-44.
6. Stewart JB, Chinnery PF. The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease. Nat Rev Genet. 2015;16:530-42.
7. Gorman GS, Chinnery PF, Dimauro S, et al. Mitochondrial diseases. Nat Rev Dis Primers. 2016;2:16080.
8. Smeitink J, Van Den Heuvel L, Dimauro S. The genetics and pathology of oxidative phosphorylation. Nat Rev Genet. 2001;2:342-52.
9. Calame DG, Emrick LT. Functional genomics and small molecules in mitochondrial neurodevelopmental disorders. Neurotherapeutics. 2024;21:e00316.
10. Klopstock T, Priglinger C, Yilmaz A, Kornblum C, Distelmaier F, Prokisch H. Mitochondrial disorders. Dtsch Arztebl Int. 2021;118:741-8.
11. Finsterer J. Genetic, pathogenetic, and phenotypic implications of the mitochondrial A3243G tRNALeu(UUR) mutation. Acta Neurol Scand. 2007;116:1-14.
12. Youle RJ, Van Der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012;337:1062-5.
13. Zheng Y, Yang J, Li X, et al. Mitochondria at the crossroads: quality control mechanisms in neuronal senescence and neurodegeneration. Neurobiol Dis. 2025;208:106862.
14. Mclaughlin KL, Mcclung JM, Fisher-Wellman KH. Bioenergetic consequences of compromised mitochondrial DNA repair in the mouse heart. Biochem Biophys Res Commun. 2018;504:742-8.
15. Dautant A, Meier T, Hahn A, Tribouillard-Tanvier D, Di Rago J, Kucharczyk R. ATP synthase diseases of mitochondrial genetic origin. Front Physiol. 2018;9:329.
16. Bazil JN, Pannala VR, Dash RK, Beard DA. Determining the origins of superoxide and hydrogen peroxide in the mammalian NADH:ubiquinone oxidoreductase. Free Radic Biol Med. 2014;77:121-9.
17. Andreyev AY, Kushnareva YE, Murphy AN, Starkov AA. Mitochondrial ROS metabolism: 10 years later. Biochemistry. 2015;80:517-31.
19. Bhatti JS, Bhatti GK, Reddy PH. Mitochondrial dysfunction and oxidative stress in metabolic disorders — A step towards mitochondria based therapeutic strategies. Biochim Biophys Acta. 2017;1863:1066-77.
20. Panov AV, Dikalov SI. Cardiolipin, perhydroxyl radicals, and lipid peroxidation in mitochondrial dysfunctions and aging. Oxid Med Cell Longev. 2020;2020:1-14.
21. Zanfardino P, Amati A, Perrone M, Petruzzella V. The balance of MFN2 and OPA1 in mitochondrial dynamics, cellular homeostasis, and disease. Biomolecules. 2025;15:433.
22. Candé C, Cohen I, Daugas E, et al. Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. Biochimie. 2002;84:215-22.
23. Kim R, Emi M, Tanabe K. Role of mitochondria as the gardens of cell death. Cancer Chemother Pharmacol. 2005;57:545-53.
24. Ahola S. Mitochondria setting the stage for ferroptosis. Trends Endocrinol Metab. 2026:S1043276026001505.
25. Kolotova A, Shestopalov A, Kutsev S. The role of apoptosis and ferroptosis in primary mitochondrial diseases: mechanisms and pathogenesis. Int J Mol Sci. 2026;27:5931.
26. Kim J, Kim H, Chung JH. Molecular mechanisms of mitochondrial DNA release and activation of the cGAS-STING pathway. Exp Mol Med. 2023;55:510-9.
27. Horssen J, Van Schaik P, Witte M. Inflammation and mitochondrial dysfunction: a vicious circle in neurodegenerative disorders? Neurosci Lett. 2019;710:132931.
28. Aguilar K, Jakubek P, Zorzano A, Wieckowski MR. Primary mitochondrial diseases: the intertwined pathophysiology of bioenergetic dysregulation, oxidative stress and neuroinflammation. Eur J Clin Investig. 2024;54:e14217.
29. Barcelos I, Shadiack E, Ganetzky RD, Falk MJ. Mitochondrial medicine therapies: rationale, evidence, and dosing guidelines. Curr Opin Pediatr. 2020;32:707-18.
30. Parikh S, Goldstein A, Koenig MK, et al. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med. 2015;17:689-701.
31. De Vries MC, Brown DA, Allen ME, et al. Safety of drug use in patients with a primary mitochondrial disease: an international Delphi‐based consensus. J Inherit Metab Dis. 2020;43:800-18.
32. Sue CM, Balasubramaniam S, Bratkovic D, et al. Patient care standards for primary mitochondrial disease in Australia: an Australian adaptation of the Mitochondrial Medicine Society recommendations. Intern Med J. 2021;52:110-20.
33. Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF; Cochrane Neuromuscular Group. Treatment for mitochondrial disorders. Cochrane Database Syst Rev. 2012:2012.
34. Reetz K, Lischewski SA, Dogan I, et al. Friedreich's ataxia—a rare multisystem disease. Lancet Neurol. 2025;24:614-24.
36. Lynch DR, Chin MP, Delatycki MB, et al. Safety and efficacy of omaveloxolone in friedreich ataxia (MOXIeStudy). Ann Neurol. 2020;89:212-25.
37. Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021;23:471-8.
38. Thompson WR, Manuel R, Abbruscato A, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024;26:101138.
39. Hornby B, Thompson WR, Almuqbil M, et al. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome. Orphanet J Rare Dis. 2022;17:336.
41. Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90:e1212-21.
42. Karaa A, Haas R, Goldstein A, Vockley J, Cohen BH. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. J Cachexia Sarcopenia Muscle. 2020;11:909-18.
43. Karaa A, Bertini E, Carelli V, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101:e238-52.
44. Karaa A, Bertini E, Carelli V, et al. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial. Orphanet J Rare Dis. 2024;19:431.
46. Domínguez-González C, Chiang C, Colson A, et al. Pyrimidine Nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency: a multicenter retrospective chart review study. Neurology. 2025;105:e213908.
47. Bermejo-Guerrero L, Hernández-Voth A, Serrano-Lorenzo P, et al. Remarkable clinical improvement with oral nucleoside treatment in a patient with adult-onset TK2 deficiency: a case report. Mitochondrion. 2024;76:101879.
48. Berrahmoune S, Dassi C, Pekeles H, et al. Investigating the safety and efficacy of deoxycytidine/deoxythymidine in mitochondrial DNA depletion disorders: phase 2 open-label trial. J Neurol. 2025;272:307.
49. Johnson SC, Yanos ME, Kayser E, et al. mTOR inhibition alleviates mitochondrial disease in a mouse model of leigh syndrome. Science. 2013;342:1524-8.
50. Sage‐schwaede A, Engelstad K, Salazar R, et al. Exploring mTOR inhibition as treatment for mitochondrial disease. Ann Clin Transl Neurol. 2019;6:1877-81.
51. Repp BM, Mastantuono E, Alston CL, et al. Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective? Orphanet J Rare Dis. 2018;13:120.
52. Plantone D, Pardini M, Rinaldi G. Riboflavin in neurological diseases: a narrative review. Clin Drug Investig. 2021;41:513-27.
53. Xu C, Jin H, Li J, et al. Deficiency of the NAD(P)HX metabolic repair system: a treatable mitochondrial disease. Orphanet J Rare Dis. 2026;21:63.
54. Invernizzi F, Panteghini C, Chiapparini L, et al. Thiamine-responsive disease due to mutation of tpk1: importance of avoiding misdiagnosis. Neurology. 2017;89:870-1.
55. Alcázar-Fabra M, Trevisson E, Brea-Calvo G. Clinical syndromes associated with Coenzyme Q10 deficiency. Essays Biochem. 2018;62:377-98.
56. Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N Engl J Med. 2008;358:2849-50.
57. Distelmaier F, Corral-Sarasa J, Jiménez-Sánchez L, et al. Preclinical and first-in-human evidence of 4-hydroxybenzoic acid for mitochondrial COQ2 deficiency. Brain. 2026;149:1784-97.
58. Canda E, Kalkan Ucar S, Coker M. Biotinidase deficiency: prevalence, impact and management strategies. Pediatric Health Med Ther. 2020;11:127-33.
59. Jiang H, Alahmad A, Fu S, et al. Identification and characterization of novel MPC1 gene variants causing mitochondrial pyruvate carrier deficiency. J Inherit Metab Dis. 2022;45:264-77.
60. Pata S, Flores-Rojas K, Gil A, et al. Clinical improvements after treatment with a low-valine and low-fat diet in a pediatric patient with enoyl-CoA hydratase, short chain 1 (ECHS1) deficiency. Orphanet J Rare Dis. 2022;17:340.
61. Sato-Shirai I, Ogawa E, Arisaka A, et al. Valine-restricted diet for patients with ECHS1 deficiency: divergent clinical outcomes in two Japanese siblings. Brain Dev. 2021;43:308-13.
62. Yang H, Yu D. Clinical, biochemical and metabolic characterization of patients with short-chain enoyl-CoA hydratase(ECHS1) deficiency: two case reports and the review of the literature. BMC Pediatr. 2020;20:50.
63. Xu Y, Zhang J, Yu K, et al. A therapeutic regimen for 3-hydroxyisobutyryl-CoA hydrolase deficiency with exercise-induced dystonia. Eur J Paediatr Neurol. 2019;23:755-9.
64. Parikh S, Goldstein A, Karaa A, et al. Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med. 2017;19:1380-97.
65. Orsucci D, Caldarazzo Ienco E, Montano V, Siciliano G, Mancuso M. Mitochondrial stroke-like episodes: the search for new therapies. Pharmacol Res. 2022;180:106228.
66. Mancuso M, Papadopoulou MT, Ng YS, et al. Management of seizures in patients with primary mitochondrial diseases: consensus statement from the InterERNs Mitochondrial Working Group. Eur J Neurol. 2024;31:e16275.
67. Na J, Lee Y. Therapeutic approach to epilepsy in patients with mitochondrial diseases. Yonsei Med J. 2025;66:131.
68. Varughese R, Rahman S. Endocrine dysfunction in primary mitochondrial diseases. Endocr Rev. 2025;46:376-96.
69. Chaudhry A, Thompson DM, Chanoine JP. Diabetes management in maternally inherited diabetes and deafness (MIDD): a review and a proposed treatment algorithm. Diabetes Obes Metab. 2025;28:826-39.
70. Sue CM, Lipsett LJ, Crimmins DS, et al. Cochlear origin of hearing loss in MELAS syndrome. Ann Neurol. 2004;43:350-9.
71. O'toole J. Renal manifestations of genetic mitochondrial disease. Int J Nephrol Renovasc Dis. 2014;7:57-67.
72. Madsen S, Allender B, Blackford R, et al. Ketogenic diet therapy in pyruvate dehydrogenase deficiency: global clinical practice from literature and survey data. Mol Genet Metab. 2026;148:110190.
73. Huang L, Li H, Zhong J, et al. Efficacy and safety of the ketogenic diet for mitochondrial disease with epilepsy: a prospective, open-labeled, controlled study. Front Neurol. 2022;13:880944.
74. Keshavan N, Minczuk M, Viscomi C, Rahman S. Gene therapy for mitochondrial disorders. J Inherit Metab Dis. 2024;47:145-75.
75. Crystal RG, Weinsaft JW, Kaminsky SM, et al. AAVrh.10hFXN gene therapy for the cardiomyopathy of friedreich ataxia: a nonrandomized clinical trial. JAMA Cardiol. 2026;11:709.
76. Faria R, Boisguérin P, Sousa Â, Costa D. Delivery systems for mitochondrial gene therapy: a review. Pharmaceutics. 2023;15:572.
77. Chen BS, Yu-Wai-Man P. From bench to bedside—delivering gene therapy for leber hereditary optic neuropathy. Cold Spring Harb Perspect Med. 2022;12:a041282.
78. Sahel J, Vignal-Clermont C, Yu-Wai-Man P, Biousse V, Blouin L, Taiel M. Neuropathie optique héréditaire de Leber: amélioration bilatérale de la vision après thérapie génique par injection unilatérale. Med Sci. 2021;37:712-5.
79. Yu-Wai-Man P, Newman NJ, Biousse V, et al. Five-year outcomes of lenadogene nolparvovec gene therapy in leber hereditary optic neuropathy. JAMA Ophthalmol. 2025;143:99.
80. Newman NJ, Yu-Wai-Man P, Subramanian PS, et al. Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy. Brain. 2023;146:1328-41.
81. Newman NJ, Biousse V, Yu-Wai-Man P, et al. Meta-analysis of treatment outcomes for patients with m.11778G>A MT-ND4 Leber hereditary optic neuropathy. Surv Ophthalmol. 2025;70:283-95.
82. Mok BY, De Moraes MH, Zeng J, et al. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature. 2020;583:631-7.
83. Cho S, Lee S, Mok YG, et al. Targeted A-to-G base editing in human mitochondrial DNA with programmable deaminases. Cell. 2022;185:1764-76.e12.
84. Lei Z, Meng H, Liu L, et al. Mitochondrial base editor induces substantial nuclear off-target mutations. Nature. 2022;606:804-11.
85. Lee S, Lee H, Baek G, Kim J. Precision mitochondrial DNA editing with high-fidelity DddA-derived base editors. Nat Biotechnol. 2022;41:378-86.
86. Mok YG, Lee JM, Chung E, et al. Base editing in human cells with monomeric DddA-TALE fusion deaminases. Nat Commun. 2022;13:4038.
88. Zhang X, Zhang X, Ren J, et al. Precise modelling of mitochondrial diseases using optimized mitoBEs. Nature. 2025;639:735-45.
89. Chen L, Hong M, Luan C, et al. Efficient mitochondrial A-to-G base editors for the generation of mitochondrial disease models. Nat Biotechnol. 2025;44:418-29.
90. Chen L, Luan C, Hong M, et al. A mitochondrial disease model is generated and corrected using engineered base editors in rat zygotes. Nat Biotechnol. 2025;44:382-6.
91. Du S, Long Q, Zhou Y, et al. Transplantation of encapsulated mitochondria alleviates dysfunction in mitochondrial and Parkinson’s disease models. Cell. 2026;189:2821-33.e23.
92. Zhang J, Liu H, Luo S, et al. Live birth derived from oocyte spindle transfer to prevent mitochondrial disease. Reprod Biomed Online. 2017;34:361-8.
93. Hyslop LA, Blakely EL, Aushev M, et al. Mitochondrial donation and preimplantation genetic testing for mtDNA disease. N Engl J Med. 2025;393:438-49.
94. Mcfarland R, Hyslop LA, Feeney C, et al. Mitochondrial donation in a reproductive care pathway for mtDNA disease. N Engl J Med. 2025;393:461-8.
95. Li W, Liao X, Lin K, et al. Earlier second polar body transfer and further mitochondrial carryover removal for potential mitochondrial replacement therapy. MedComm. 2023;4:e217.
96. Liao X, Li W, Lin K, et al. Significant decrease of maternal mitochondria carryover using optimized spindle-chromosomal complex transfer. PLoS Biol. 2023;21:e3002313.
97. Sato Y, Nakagawa M, Higuchi I, Osame M, Naito E, Oizumi K. Mitochondrial myopathy and familial thiamine deficiency. Muscle Nerve. 2000;23:1069-75.
98. Bernsen P, Gabreëls F, Ruitenbeek W, Hamburger H. Treatment of complex I deficiency with riboflavin. J Neurol Sci. 1993;118:181-7.
99. Glover EI, Martin J, Maher A, Thornhill RE, Moran GR, Tarnopolsky MA. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve. 2010;42:739-48.
100. Neugebauer J, Reinson K, Bellusci M, et al. Current global vitamin and cofactor prescribing practices for primary mitochondrial diseases: Results of a European reference network survey. J Inherit Metab Dis. 2024;48:e12805.
101. Panetta J, Smith LJ, Boneh A. Effect of high‐dose vitamins, coenzyme Q and high‐fat diet in paediatric patients with mitochondrial diseases. J Inherit Metab Dis. 2004;27:487-98.
102. Gimenes A, Bravo D, Nápolis L, et al. Effect of L-carnitine on exercise performance in patients with mitochondrial myopathy. Braz J Med Biol Res. 2015;48:354-62.
103. Ikawa M, Povalko N, Koga Y. Arginine therapy in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Curr Opin Clin Nutr Metab Care. 2020;23:17-22.
104. Koga Y, Povalko N, Inoue E, et al. Therapeutic regimen of l-arginine for MELAS: 9-year, prospective, multicenter, clinical research. J Neurol. 2018;265:2861-74.
105. Ortigoza-escobar JD, Molero-luis M, Arias A, et al. Treatment of genetic defects of thiamine transport and metabolism. Expert Rev Neurother. 2016;16:755-63.
